
Opthea (OPT) Stock Forecast & Price Target
Opthea (OPT) Analyst Ratings
Bulls say
Opthea Ltd is focused on developing innovative biologic therapies, particularly OPT-302, aimed at treating eye diseases linked to blood and lymphatic vessel growth. Positive preliminary results from the Phase 2b trial demonstrate significant visual acuity improvements, with a notable 5.7 letter gain in certain patient subgroups, potentially exceeding the efficacy thresholds required for successful pivotal trial outcomes. As the company heads towards the Phase 3 COAST trial's topline results expected in early Q2 CY2025, optimism grows regarding the broader adoption of its treatments, underpinned by supportive payer sentiment around meaningful vision improvement metrics.
Bears say
Opthea Ltd reported a substantial net loss of $131.9 million, or $0.11 per share, for the first half of FY 25, indicating significant financial challenges. The company's outlook remains negative due to critical risks, including the potential failure of its developmental candidate OPT-302 to meet revenue expectations, difficulties in securing the necessary capital resources for its operations, and ongoing uncertainty in the development and commercialization of its products. These factors collectively raise concerns about the company's ability to achieve sustainable growth and profitability in the highly competitive medical technology and healthcare sector.
This aggregate rating is based on analysts' research of Opthea and is not a guaranteed prediction by Public.com or investment advice.
Opthea (OPT) Analyst Forecast & Price Prediction
Start investing in Opthea (OPT)
Order type
Buy in
Order amount
Est. shares
0 shares